Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sanj Patel Sells 7,278 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 7,278 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $50.01, for a total transaction of $363,972.78. Following the transaction, the chief executive officer owned 7,278 shares in the company, valued at $363,972.78. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA traded down $1.91 during mid-day trading on Wednesday, reaching $47.03. 600,454 shares of the company traded hands, compared to its average volume of 647,366. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $18.25 and a fifty-two week high of $50.03. The firm has a market cap of $3.60 billion, a PE ratio of 63.55 and a beta of 0.06. The stock has a fifty day simple moving average of $45.75 and a 200-day simple moving average of $42.13.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The company had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. During the same quarter in the prior year, the business earned ($0.12) EPS. Kiniksa Pharmaceuticals International’s revenue was up 65.0% compared to the same quarter last year. As a group, analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. Qube Research & Technologies Ltd boosted its stake in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares during the period. Rubric Capital Management LP boosted its stake in Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after purchasing an additional 526,567 shares during the period. Cubist Systematic Strategies LLC boosted its stake in Kiniksa Pharmaceuticals International by 213.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after purchasing an additional 447,536 shares during the period. Spruce Street Capital LP acquired a new position in Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $17,943,000. Finally, SG Americas Securities LLC boosted its stake in Kiniksa Pharmaceuticals International by 288.6% in the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock worth $22,333,000 after purchasing an additional 402,078 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and a consensus target price of $55.29.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.